ENTA
NASDAQ HealthcareEnanta Pharmaceuticals, Inc. - Common Stock
Biotechnology
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
๐ Market Data
| Price | $11.15 |
|---|---|
| Volume | 218,488 |
| Market Cap | 324.75M |
| Beta | 0.960 |
| RSI (14-Day) | 36.0 |
| 200-Day MA | $13.21 |
| 50-Day MA | $12.58 |
| 52-Week High | $17.15 |
| 52-Week Low | $10.22 |
| Forward P/E | -4.70 |
| Price / Book | 3.21 |
๐ฏ Investment Strategy Scores
ENTA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (86/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ENTA in your text
Paste any article, transcript, or post โ the tool will extract ENTA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.